PPARδ comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
==== Positive criminology and positive victimology ==== Positive criminology and positive victimology are conceptual approaches, developed by the Israeli criminologist Natti Ronel and his research team, that follow principles of positive psychology and apply them into the fields of criminology and victimology, respectively. Positive criminology and victimology both place an emphasis on social inclusion and on unifying and integrating forces at individual, group, social and spiritual levels that are associated with the limiting of crime and recovery from victimization. In traditional approaches, the study of crime, violence and related behaviors emphasizes the negative aspects in people's lives that are associated with deviance, criminality and victimization. A common understanding is that human relationships are affected more by destructive encounters than by constructive or positive ones. Positive criminology and victimology argue that a different approach is viable, based on three dimensions – social integration, emotional healing and spirituality – that constitute positive direction indicators.
Intravascular hemolysis describes hemolysis that happens mainly inside the vasculature. As a result, the contents of the red blood cell are released into the general circulation, leading to hemoglobinemia and increasing the risk of ensuing hyperbilirubinemia. Intravascular hemolysis may occur when red blood cells are targeted by autoantibodies, leading to complement fixation, or by damage by parasites such as Babesia. Additionally, thrombotic microangiopathy (TMA) can result in hemolysis of red blood cells. TMA is frequently observed in aHUS patients where clots form in the small vessels of the kidney resulting in damaged red blood cells as they attempt to pass through the restricted vessels.
The developer of the Half-Life series, Valve, was founded in 1996 in Kirkland, Washington by the former Microsoft employees Mike Harrington and Gabe Newell. Valve began working on the first Half-Life soon after formation, and settled on a concept for a horror-themed 3D action game, using the Quake engine as licensed by id Software. The game was a hit at the 1997 E3 convention, where its animation system and artificial intelligence were demonstrated. The success led to its first expansion pack, Half-Life: Opposing Force, which was developed by Gearbox Software, a new company based in Plano, Texas, and announced on April 15, 1999. The Gearbox founder, Randy Pitchford, said Valve gave them the project to allow Valve to focus on future games. Opposing Force was demonstrated at the 1999 E3 convention, where new locations, characters and the story were revealed. The second Half-Life expansion pack, Half-Life: Blue Shift, was again developed by Gearbox Software and announced by its publisher, Sierra Entertainment, on August 30, 2000. Sierra intended to release Blue Shift for the Dreamcast, and it was set to include higher detail models and textures that were double the polygon count of the models from Half-Life. However, after several months of delays, Sierra terminated the Dreamcast version of Blue Shift on June 16, 2001, and instead released it for Windows on June 12. Afterward, Gearbox began working on a Half-Life game for the PlayStation 2.
Since ABA dissipates slowly from the tissues and its effects take time to be offset by other plant hormones, there is a delay in physiological pathways that provides some protection from premature growth. Abscisic acid accumulates within seeds during fruit maturation, preventing seed germination within the fruit or before winter. Abscisic acid's effects are degraded within plant tissues during cold temperatures or by its removal by water washing in and out of the tissues, releasing the seeds and buds from dormancy. ABA exists in all parts of the plant, and its concentration within any tissue seems to mediate its effects and function as a hormone; its degradation, or more properly catabolism, within the plant affects metabolic reactions and cellular growth and production of other hormones. Plants start life as a seed with high ABA levels. Just before the seed germinates, ABA levels decrease; during germination and early growth of the seedling, ABA levels decrease even more. As plants begin to produce shoots with fully functional leaves, ABA levels begin to increase again, slowing down cellular growth in more "mature" areas of the plant. Stress from water or predation affects ABA production and catabolism rates, mediating another cascade of effects that trigger specific responses from targeted cells. Scientists are still piecing together the complex interactions and effects of this and other phytohormones. In plants under water stress, ABA plays a role in closing the stomata.
=== Hyperthermia === Hyperthermia is an elevation of body temperature over the temperature set point, due to either too much heat production or not enough heat loss. Hyperthermia is thus not considered fever. Hyperthermia should not be confused with hyperpyrexia (which is a very high fever). Clinically, it is important to distinguish between fever and hyperthermia as hyperthermia may quickly lead to death and does not respond to antipyretic medications. The distinction may however be difficult to make in an emergency setting, and is often established by identifying possible causes.
Sources: en.wikipedia.org
Beak trimming (also spelled as beak-trimming; informally as debeaking), or beak conditioning, is the partial removal of the beak of poultry, especially layer hens and turkeys, although it is also performed on some quail and ducks. When multiple birds are confined in small spaces, they are more likely to hurt each other through pecking. Beak trimming aims to avoid damage done by pecking, although the practice is criticized by animal welfare organizations and banned in several European countries. Beak trimming is most common in egg-laying strains of chickens. In some countries, such as the United States, turkeys routinely have their beaks trimmed. In the UK, only 10% of turkeys are beak trimmed. In close confinement, cannibalism, feather pecking and aggression are common among turkeys, ducks, pheasants, quail, and chickens of many breeds (including both heritage breeds and modern hybrids) kept for eggs. The tendency to cannibalism and feather pecking varies among different strains of chickens, but does not manifest itself consistently. Some flocks of the same breed may be entirely free from cannibalism, while others, under the same management, may have a serious outbreak. Mortalities, mainly due to cannibalism, can be up to 15% in egg laying flocks housed in aviaries, straw yards, and free-range systems. Because egg laying strains of chickens can be kept in smaller group sizes in caged systems, cannibalism is reduced leading to a lowered trend in mortality as compared to non-cage systems.
== Mitchell Report == He was named in the Mitchell Report on Steroid Abuse in Baseball on December 13, 2007. According to the report, Bigbie admitted to purchasing and using a variety of performance-enhancing substances from Kirk Radomski from 2001 to 2005, including human growth hormone, Deca-Durabolin, Sustanon, testosterone, and anti-estrogen drugs. Bigbie was introduced to Radomski through former teammate David Segui. Segui reportedly instructed him on "training regimens and the use of creatine, a legal muscle builder, before teaching him about steroids and eventually injecting him with Deca-Durabolin". After he started using steroids, Bigbie gained 30 pounds while maintaining a body fat percentage of 7%.
Volanesorsen was approved by the European Medicines Agency (EMA) for the treatment of familial chylomicronaemia syndrome in May 2019. In January 2013 mipomersen (marketed as Kynamro) was approved by the FDA for the treatment of homozygous familial hypercholesterolemia. Inotersen received FDA approval for the treatment of hereditary transthyretin-mediated amyloidosis in October 2018. The application for inotersen was granted orphan drug designation. It was developed by Ionis Pharmaceuticals and licensed to Akcea Therapeutics. Patisiran (sold under Onpattro) was developed by Alnylam Pharmaceuticals, and also approved for use in the US and EU in 2018 with orphan drug designation. Its mechanism-of-action is the active substance of small interfering RNA (siRNA), which allows it to interfere with and block the production of transthyretin. As such, it was the first FDA-approved siRNA therapeutic.
16O + γ → 15O + n 14N + γ → 13N + n 15O decays to 15N, emitting a positron. The positron quickly annihilates with an electron, producing two gamma rays of about 511 keV. After a lightning bolt, this gamma radiation dies down with half-life of 2 minutes, but these low-energy gamma rays go on average only about 90 metres through the air. Together with rays produced from positrons from nitrogen-13 they may only be detected for a minute or so as the "cloud" of 15O and 13N floats by, carried by the wind.
Sources: en.wikipedia.org
Southern Rhodesia's fighting contributions in Britain and western Europe were primarily in the air, as part of the much larger Allied forces. Rhodesian pilots and Allied airmen trained in the colony's flying schools participated in the defence of Britain throughout the war, as well as in the strategic bombing of Germany and other operations. Rhodesia provided the only RAF flying ace of the Norwegian Campaign of April–June 1940, Squadron Leader Caesar Hull. Later that year "The Few", the Allied airmen of the Battle of Britain, included three pilots of Southern Rhodesian birth—Hull, Pilot Officer John Chomley and Flight Lieutenant John Holderness—of whom two, Hull and Chomley, lost their lives. Two of the RAF's three Rhodesian squadrons, Nos. 44 and 266, operated from England during the war. No. 266 (Rhodesia) Squadron, a fighter squadron based in Cambridgeshire for most of the duration, was initially only nominally Rhodesian, being manned by a mixture of British and Commonwealth personnel, but it received more airmen from the colony gradually and was virtually all Rhodesian by August 1941. Initially flying Spitfires, it switched to Typhoons in early 1942. It took as its motto the Sindebele word Hlabezulu ("Stabber of Skies") and first went into action over Dunkirk on 2 June 1940, after which it fought in the Battle of Britain. The squadron's duties thereafter included patrolling, protecting convoys, sweeping around northern France and the Belgian and Dutch coasts, and escorting bombing raids over France and the Rhine. No.
=== Sleep problems === Sleep disturbances are extremely common in fibromyalgia and may occur in up to 90% of patients. These disturbances frequently include non-restorative sleep, morning tiredness, and daytime somnolence. Although patients often report poor sleep quality, insomnia itself is not considered a typical or defining feature of fibromyalgia. Instead, individuals may obtain a normal duration of sleep but still wake feeling unrefreshed due to abnormalities in sleep architecture and pain-related disruptions in restorative sleep stages. A meta-analysis compared quantitative and qualitative sleep metrics in people with fibromyalgia and healthy people. Individuals with fibromyalgia reported lower sleep quality and efficiency, longer wake time after sleep onset, shorter sleep duration, lighter sleep, and greater difficulty initiating sleep, both quantitatively and qualitatively. Improving sleep quality can help people with fibromyalgia manage pain.
are the mass diffusivity and thermal conductivity. The fact that mass, momentum, and energy (heat) transport are among the most relevant processes in continuum mechanics is not a coincidence: these are among the few physical quantities that are conserved at the microscopic level in interparticle collisions. Thus, rather than being dictated by the fast and complex microscopic interaction timescale, their dynamics occurs on macroscopic timescales, as described by the various equations of transport theory and hydrodynamics.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.